Please use this identifier to cite or link to this item:
|Title:||Rituximab : a novel treatment for Pemphigus in Malta|
Boffa, Michael J.
|Keywords:||Pemphigus -- Pathophysiology|
Pemphigus -- Treatment
Immune response -- Regulation
Biological response modifiers
|Publisher:||University of Malta. Medical School|
|Citation:||Boffa, M., Mintoff, D., Mercieca, L., Cassar, D., Cauchi, S., Boffa, M. J., & Scerri, L. (2017). Rituximab : a novel treatment for Pemphigus in Malta. Malta Medical School Gazette, 1(4), 15-22.|
|Abstract:||Until recently, the main treatment for pemphigus has been systemic corticosteroids, usually administered at high doses with consequent side-effects. Lately, the biological agent rituximab has been introduced as an effective treatment for this condition. This article describes seven cases of pemphigus successfully treated with rituximab in Malta and discusses the benefits and drawbacks of this novel treatment modality.|
|Appears in Collections:||MMSG, Volume 1, Issue 4|
MMSG, Volume 1, Issue 4
Scholarly Works - FacM&SMed
Scholarly Works - FacM&SPsy
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.